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A B S T R A C T
Purpose
The ongoing integration of cancer genomic testing into routine clinical care has led to increased
demand for cancer genetic services. To meet this demand, there is an urgent need to enhance the
accessibility and reach of such services, while ensuring comparable care delivery outcomes. This
randomized trial compared 1-year outcomes for telephone genetic counseling with in-person coun-
seling among women at risk of hereditary breast and/or ovarian cancer living in geographically diverse
areas.
Patients and Methods
Using population-based sampling, women at increased risk of hereditary breast and/or ovarian
cancer were randomly assigned to in-person (n = 495) or telephone genetic counseling (n = 493).
One-sided 97.5% CIs were used to estimate the noninferiority effects of telephone counseling on
1-year psychosocial, decision-making, and quality-of-life outcomes. Differences in test-uptake pro-
portions for determining equivalency of a 10% prespecified margin were evaluated by 95% CIs.
Results
At the 1-year follow-up, telephone counseling was noninferior to in-person counseling for all
psychosocial and informed decision-making outcomes: anxiety (difference [d], 0.08; upper bound
97.5% CI, 0.45), cancer-specific distress (d, 0.66; upper bound 97.5% CI, 2.28), perceived personal
control (d, 20.01; lower bound 97.5% CI, 20.06), and decisional conflict (d, 20.12; upper bound
97.5% CI, 2.03). Test uptake was lower for telephone counseling (27.9%) than in-person counseling
(37.3%), with the difference of 9.4% (95% CI, 2.2% to 16.8%). Uptake was appreciably higher for
rural compared with urban dwellers in both counseling arms.
Conclusion
Although telephone counseling led to lower testing uptake, our findings suggest that telephone
counseling can be effectively used to increase reach and access without long-term adverse psy-
chosocial consequences. Further work is needed to determine long-term adherence to risk man-
agement guidelines and effective strategies to boost utilization of primary and secondary preventive
strategies.
J Clin Oncol 34:2914-2924. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Increased awareness of associations between
BRCA1/2 mutations and breast and ovarian
cancer1-10 has led to an increased demand for
genetic counseling and testing.11,12 If population-
wide BRCA1/2 screening is realized,13 the need for
evidence-based and efficient counseling care de-
livery models will also increase. Specialized ex-
pertise is required to assess a woman’s risk of
hereditary breast and ovarian cancer (HBOC),
support informed decision-making, provide risk-
appropriate care recommendations, and attend to
the potential deleterious psychosocial effects of
providing new risk information.14 Providers often
lack this specialized knowledge15,16 leading to
suboptimal patient informed decision-making
and avoidable distress.17,18 Increasing access to
trained genetic counselors is therefore essential.19
Telephone counseling can extend the reach
of trained genetic counselors and overcome
2914 © 2016 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 24 • AUGUST 20, 2016
geographic access barriers16,20-26 while reducing costs.27,28 Con-
cerns remain, however, about whether telephone counseling can
support informed decision-making and minimize adverse psy-
chologic outcomes.12,29-31 Recent evidence indicates that in the
short term, telephone counseling is noninferior to in-person coun-
seling for key decision-making and psychosocial outcomes.27,32 There
are no data on longer-term noninferiority for these outcomes after
telephone counseling.33-39
To fill this gap, we examined 1-year outcomes from a pre-
viously reported randomized trial32 comparing telephone with in-
person counseling in a population with potential geographic
barriers to care. We hypothesized that telephone counseling would
be noninferior to in-person counseling at the 1-year follow-up
for psychologic, informed decision-making, quality-of-life, and
risk management outcomes. We also assessed geographic dif-
ferences in follow-up outcomes and described risk management
behaviors.
PATIENTS AND METHODS
Research Design and Study Population
A two-armed, parallel-cluster, randomized equivalency/noninferiority
trial compared telephonewith in-person counseling for deleterious BRCA1/2
mutations (NCT01346761). Enrollment began August 2010 and ended
September 2012. One-year outcome assessments were completed February
2014. Study details and short-term outcomes have been previously
published.32
The Utah Population Database40 and Utah Cancer Registry were used
to identify and recruit breast and ovarian cancer survivors. At-risk female
relatives were recruited through survivors who tested positive for a BRCA1/2
mutation. Eligible participants were English speaking, 25 to 74 years of age,
Utah residents, had personal/family histories meeting HBOC genetic testing
guidelines,41 had telephone access, could travel to in-person counseling at
one of 14 clinics, and had no prior genetic counseling and/or BRCA1/2
testing. The University of Utah and University of New Mexico Institutional
Review Boards approved study protocol. All participants provided informed
consent.
Randomization and Masking
Participants completed baseline assessments and were randomized by
family unit to one of the two study arms using a computer-generated
allocation algorithm based on a permuted block randomization plan.32
Study staff who conducted baseline assessments were blinded to the
identity of a woman’s participating relative(s).
Interventions
In-person counseling. Women assigned to in-person counseling re-
ceived counseling by a cancer genetic counselor according to a standardized
protocol consistent with national guidelines32,42,43 and were given an
HBOC educational brochure and a copy of the visual aids used during the
counseling. Women who decided to have genetic testing could provide
a sample at their appointment or bring a BRCA1/2 buccal test kit home
should they decide to test at a later time. Women who chose testing were
offered post-test counseling with the same genetic counselor who per-
formed pre-test counseling. Test result–specific visual aids and recom-
mendations for both positive and negative test results were used.
Telephone counseling. Women assigned to telephone counseling re-
ceived counseling by a cancer genetic counselor according to the same
standardized protocol as those in the in-person counseling arm. They were
mailed sealed packets containing the same print materials used for in-
person counseling, which were to be opened and used at the time of their
telephone counseling session. Women who decided to have genetic testing
were mailed a genetic test buccal kit. Post-test counseling was delivered by
the same genetic counselor using the same tailored visual aids based on the
results. Participants in both arms were mailed a letter summarizing their
personalized risk assessment based on family history and/or genetic test
result and management recommendations. Both groups were asked to
identify their healthcare provider(s) to also receive the letter.
Data collection and measures. Data collectors, who were blinded to
intervention assignment, collected self-reported data via telephone, In-
ternet, or mailed surveys. Assessments were done at baseline, 1 week after
pre-test and post-test counseling, 6 months, and 1 year after the last
counseling session. This study focuses on 1-year outcomes.
Anxiety was measured at baseline and 1 year with the six-item state
anxiety subscale of the Brief Symptom Inventory-18.44 Higher scores
indicate more anxiety (Cronbach’s a coefficient = .90 to .91).
Cancer-specific distress was measured at baseline and 1 year with the
15-item Impact of Event Scale.45 Higher scores indicate more distress
(a = .89 to .90).
Mental and physical health-related quality of life was measured at
baseline and 1 year with the 12-item Short Form Health Survey (SF-12,
version 2).46,47 Higher scores reflect better quality of life for the mental
(a = .84) and physical (a = .88) component summary scores.
Perceived control about risk of HBOC (ie, “the problem”) was
assessed at 1 year with the nine-item Perceived Personal Control Ques-
tionnaire.31 The questionnaire assesses three dimensions of control:
cognitive (eg, “I feel I understand the problem that brought me to genetic
counseling”), behavioral (eg, “I know what I can do to alleviate the
problem”), and decisional (eg, “I feel I can make decisions that would
influence future outcomes”). Higher scores indicate more perceived
control (a = .85).
Decisional conflict associated with the BRCA1/2 testing decision was
measured with the 16-item version of the Decisional Conflict Scale at
1 year.48,49 Higher scores indicate more decisional conflict (a = .92).
Decisional regret about BRCA1/2 testing decisions were measured
with the five-item Decision Regret Scale at 1 year.50 Higher scores indicate
more decisional regret (a = .91).
Risk management behaviors. Participants were provided with risk
management recommendations, which were based on National Com-
prehensive Cancer Network guidelines and tailored to their personal
cancer status, genetic test results, and presence of breast and ovaries
(Appendix Table A1, online only). Counseling recommendations re-
flected the guidelines for surveillance at the time of the study.51,52 Breast
cancer screening, prophylactic mastectomy, and oophorectomy were
assessed.51,53
Statistical Analysis
The a priori primary noninferiority outcomes were 1-year changes
from baseline in anxiety and cancer-specific distress. Noninferiority
margins reflected established clinically significant change (cancer-
specific distress and decisional conflict: 4 points; mental and physical
quality of life: 22.5 points).45,46,50 In accordance with other stud-
ies and literature on meaningful changes in health,54 a margin of no
more than 0.5 standard deviation “worse” than the in-person coun-
seling mean value was used for measures without clinical guidelines
(decisional regret and anxiety: 5 points; perceived personal control:
20.2 points).
The primary noninferiority analyses were based on the available
sample at baseline and 1 year.55-57 Missing scores were substituted with
estimates biased toward inferiority: substituting in-person counseling
missing observations with the mean of in-person counseling, and replacing
telephone counseling missing observations with the mean plus the non-
inferiority margin of in-person counseling. To test that telephone coun-
seling was not unacceptably worse than in-person counseling, one-sided
97.5% cluster bootstrap CIs with 1,000 replications were used to estimate
the noninferiority effects for the between-group intervention differences,
while accounting for the potential correlation among subjects within the
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family. The same approach was used for the exploratory analysis of the
noninferiority effects for geographic (rural v urban) and genetic test status
(tester v nontester) subgroups.
The equivalency of genetic testing uptake between telephone and in-
person counseling within 1 year of the precounseling session was a sec-
ondary outcome. A sensitivity analysis showed that results did not differ
when including or excluding women who reported testing outside the
study; therefore, testing status included all women who had either study-
verified testing (n = 240) or testing outside the study (n = 21). To test
whether the interventions had equivalent rates of genetic testing uptake by
1 year and to exclude a potential clinically relevant difference, a two-sided
95% CI was estimated from 1,000 cluster bootstrap samples for the dif-
ference in uptake proportions (equivalence range 6 10%) for the per-
protocol and intent-to-treat equivalency analyses, accounting for the
correlation within families.58 For the intent-to-treat analysis, the multiple
imputation method59,60 was used to impute the missing observations using
cancer status, number of relatives with cancer, education level, and health
insurance status. We also delineated risk management behaviors across the
two interventions, by cancer and by genetic testing result status.
All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary,
NC) and R 3.2.1 (R Development Core Team, Vienna, Austria).
Sample Size and Power Evaluation
Sample size and power calculations were based on the trial’s 6-month
primary outcome analysis using NQuery Advisor 7.0.32,61 Based on the
final randomized sample size of 988, 79% retention, a mean cluster size of
1.02, and an estimated intraclass coefficient of 0.07, our ad hoc power
was . 80% to detect noninferiority in cancer-specific distress and anxiety
at 1 year, with an a level of 0.05.
RESULTS
Study enrollment, randomization, and retention data are shown in
the CONSORT flow diagram (Fig 1). The study arms did not differ
at baseline (Tables 1, 2, and 3).
Psychosocial and Informed Decision-Making Outcomes
Table 2 shows measures of psychologic distress and well-
being by telephone and in-person counseling arms for the more
conservative per-protocol analysis. The mean differences for
participant-reported measures between the arms for noninferiority
measures from baseline and 1-year follow-up values were all within
the prespecified margins (Fig 2 and Table 4). No differences were
observed for noninferiority based on rural versus urban residence
or test uptake (Table 3), cancer cases (Appendix Table A2, online
only), or uninformative and nontester result status (Appendix
Table A3, online only). Results were similar for imputed data (data
not shown). Missing data for these analyses ranged from 17% to
28%.
Genetic Testing
At 1 year, 27.9% of telephone counseling and 37.3% of in-
person counseling participants underwent genetic testing. A 95%
CI of the difference in the testing uptake was 2.2% to 16.8%, which
falls outside of the equivalence range (210% to 10%). Similar
results were observed for imputed data (difference = 8.2%; 95%CI,
0.9% to 15.4%). Testing uptake was appreciably higher for rural
compared with urban dwellers in both arms (rural telephone
counseling: 38.7% [95% CI, 26.2% to 50.0%]; urban telephone
counseling: 25.9% [95% CI, 21.1% to 30.9%]; rural in-person
counseling: 41.3% [95% CI, 29.1% to 53.9%]; urban in-person
counseling: 36.6% [95% CI, 30.8% to 42.8%]).
Risk Management Behaviors
Risk management behaviors based on testing status and
previous cancer diagnosis are shown in Table 5. Three out of 20
women, who were BRCA1/2 positive and had at least one breast
before testing, had a prophylactic mastectomy (telephone coun-
seling: 10% [one of 10 women]; in-person counseling: 20% [two of
10 women]). Six of 10 women $ 35 years old, who were BRCA1/2
positive and had at least one ovary, underwent a prophylactic
oophorectomy (telephone counseling: 50% [two of four women];
in-person counseling: 67% [four of six women]). Most women
whose test results were uninformative or who did not undergo
testing were up to date with breast cancer screening guidelines
based on personal and family history. Significance tests were not
conducted because of small subgroup sample size.
DISCUSSION
This trial provides important evidence that telephone genetic
counseling for HBOC is noninferior to in-person counseling
and can be delivered as safely as in-person counseling without
an adverse effect on long-term psychologic, quality-of-life, and
decision-making outcomes. This conclusion was robust across
subgroups of participants, including those living in geographically
remote areas and those choosing to be tested or not. The vast
majority of participants received uninformative test results. Thus,
noninferiority for women with BRCA1/2 mutations or variants of
uncertain significance cannot be certain from our data because of
small subgroups.
Overall, our findings are concordant with previous research
that established nonequivalency of telephone counseling up to
6 months after genetic counseling27,32 and provide further evi-
dence that telephone genetic counseling for HBOC can be de-
livered safely.62 However, consistent with earlier reports focused on
shorter-term outcomes,27,32 at 12 months, telephone counseling
continued to generate lower genetic testing rates (27.9%) than in-
person counseling (37.3%) at 1 year. Reasons for this are unclear
but may be due to travel time to mail test kits, a delay between
telephone counseling and testing at home that might have reduced
enthusiasm for testing, or the wait between telephone counseling
and testing at home provided opportunity to further consider
potential out-of-pocket expenses or to discuss testing with social
network members. Future research is needed to better understand
how counseling mode might influence testing uptake rates and
whether the women at lowest risk are opting appropriately to forgo
testing.
Rural women had higher test uptake rates in both the tele-
phone and in-person counseling arms, suggesting that BRCA1/2
testing interests were satisfied by expanding access to genetic
counseling through the two modalities.16,22,23 One explanation for
this is that urban women most interested in testing may have had
access to genetic testing before the study. Many urban women may
have been tested and were therefore not eligible for the trial. Thus,
2916 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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Assessed for eligibility
(N = 2,035); families (N = 1,998)
Families (n = 988)
Randomly assigned (n = 1,012) 
Not randomly assigned (n = 1,023);
families (n = 1,017)*
Did not meet inclusion criteria
Refused to participate
Baseline survey not completed
(n = 835)
(n = 146)
(n = 42)
Assigned to in-person counseling (n = 510); families (n = 494)
Received pre-test counseling
Not eligible for inclusion
Previous GC and/or testing
Personal/family history not suggestive of
HBOC 
Other
Did not complete intervention
Did not receive pre-test counseling
Died 
(n = 441)
(n = 69)
(n = 11)
(n = 7)
(n = 1)
(n = 3)
(n = 57)
(n = 1)
Analyzed
1-year assessments
Available participants†
12-month (range, 354 to 382)
Intent-to-treat (n = 495); families (n = 479)‡
(n = 383)
(n = 418)
(n = 35)
(n = 30)
(n = 2)
(n = 3)
12-month follow-up
Completed 
Not completed
Not returned
Withdrew
Died
Withdrew
Died (n = 1)
(n = 13)
Completed pre-test counseling (n = 437); families (n = 421)
Died
Withdrew at 1-week follow-up
(n = 1)
(n = 4)
Not eligible for inclusion (n = 4)
Testers completed
post-test counseling
(n = 139)
Assigned to telephone counseling (n = 502); families (n = 494)
Received pre-test counseling
Did not receive pre-test counseling
Not eligible for inclusion
Previous GC and/or testing
Personal/family history not suggestive 
  of HBOC
Did not complete intervention
(n = 467)
(n = 35)
(n = 6)
(n = 4)
(n = 2)
(n = 29)
Analyzed
1-year assessments
Available participants† 
12-month (range, 377 to 403)
Intent-to-treat (n = 493); families (n = 485)‡
Withdrew
Died
(n = 10)
(n = 2)
Completed
Not completed
12-month follow-up
Not returned
Withdrew
Died
(n = 448)
(n = 39)
(n = 409)
(n = 35)
(n = 4)
(n = 0)
Not eligible for inclusion (n = 3)
Testers completed
post-test counseling
(n = 101)
Completed pre-test counseling (n = 464); families (n = 456)
Withdrew at 1-week follow-up
Died
(n = 4)
(n = 0)
Fig 1. CONSORT diagram. *Seven families had at least onemember randomly assigned and onemember not randomly assgned. †Total number of participants depends
on completion of intervention and completion of measure. ‡Intent-to-treat refers to data analysis after imputation of unknown testing uptake. GC, genetic counseling;
HBOC, hereditary breast and ovarian cancer.
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the urban sample may have been biased toward women who were
less interested in testing. Nonetheless, the rates of testing in
our study are substantially lower than in other studies where
women who were members of families with a known deleterious
mutation27,63,64 were self- or physician-referred, but similar to
a study of African American women.65
A contributing factor to the lower overall uptake of testing in
this study may be the active recruitment strategy, which identified
eligible women from population-based sources without any direct
involvement of or referral from their primary health care pro-
viders. In general, recommendations from a health care provider
strengthen perceptions about the importance of recommendations.66
Outcomes of telephone and in-person genetic counseling will
likely be optimal when integrated into the health care system and
the messages are supported and reinforced by the patient’s entire
health care team.
To our knowledge, our study is the first to assess risk man-
agement outcomes at 1 year after telephone and in-person
counseling. The majority of women adhered to screening clini-
cal breast examination and mammography guidelines (although
not for breast magnetic resonance imaging [MRI]). Uptake of
breast MRI was low, but during the timeframe of the study,
guidelines for use of breast MRI only addressed at-risk individuals,
and there were no formal guidelines recommending breast MRI
Table 1. Characteristics by Overall Sample and by Intervention Group
Characteristic Overall, % (No.; N = 988) Telephone, % (No.; n = 493) In Person, % (No.; n = 495)
Age, years
Mean 6 SD 56.1 6 8.2 56.2 6 8.1 55.9 6 8.3
Self-reported race/ethnicity
Non-Hispanic white 94.1 (930) 95.7 (472) 92.5 (458)
Hispanic 3.2 (32) 2.0 (10) 4.4 (22)
Other 2.6 (26) 2.2 (11) 3.0 (15)
Self-reported Ashkenazi Jewish ancestry
Yes 0.9 (9) 1.2 (6) 0.6 (3)
No 99.1 (979) 98.8 (487) 99.4 (492)
Marital status
Married or living as married 79.3 (784) 80.1 (395) 78.6 (389)
Single/widowed/separated/divorced 20.6 (204) 19.9 (98) 21.4 (106)
Educational level
High school or less 21.8 (215) 23.5 (116) 20.0 (99)
Some college, associates degree, or vocational school 37.9 (374) 34.3 (169) 41.4 (205)
Bachelor’s degree or higher 40.4 (399) 42.2 (208) 38.6 (191)
Rural v urban residence*
Urban 85.4 (844) 84.8 (418) 86.1 (426)
Rural 14.6 (144) 15.2 (75) 13.9 (69)
Yearly household income, $
# 29,999 13.0 (128) 14.0 (69) 11.9 (59)
30,000-49,999 19.2 (190) 17.0 (84) 21.4 (106)
50,000-69,999 19.0 (188) 19.1 (94) 19.0 (94)
$ 70,000 45.0 (445) 44.8 (221) 45.3 (224)
Missing data 3.7 (37) 5.1 (25) 2.4 (12)
Employment status
Employed (for wages or self-employed) 62.0 (613) 61.1 (301) 63.0 (312)
Not employed 38.0 (375) 38.9 (192) 37.0 (183)
Health care coverage
Yes 96.9 (957) 95.5 (471) 98.2 (486)
No 3.1 (31) 4.5 (22) 1.8 (9)
Has a personal health care provider
Yes 88.7 (876) 88.6 (437) 88.7 (439)
No 11.3 (112) 11.4 (56) 11.3 (56)
Personal history of breast and/or ovarian/fallopian tube/
peritoneal cancer
Yes 97.6 (964) 98.4 (485) 96.8 (479)
No 2.4 (24) 1.6 (8) 3.2 (16)
Recruited relatives of BRCA1/2 carriers
Yes 2.5 (25) 1.6 (8) 3.4 (17)
No 97.5 (963) 98.4 (485) 96.6 (478)
Number of first- and second-degree relatives with breast or
ovarian cancer
0 FDR and 0 SDR 52.2 (516) 51.9 (256) 52.5 (260)
1 FDR or 1 SDR 27.8 (275) 26.6 (131) 29.1 (144)
2 or more FDR/SDR 19.9 (197) 21.5 (106) 18.4 (91)
Abbreviations: FDR, first-degree relative; SDR, second-degree relative.
*Rural or urban residencewas based onRural-Urban Commuting Area (RUCA) codes at the zip code level. RUCA codeswere developed by the University ofWashington
Rural Health Research Center and the United States Department of Agriculture Economic Research Service (ERS), with the support of the federal Health Resource and
Service Administration’s Office of Rural Health Policy and the ERS, using standard Census Bureau urbanized area and urban cluster definitions in combination with work
commuting data to characterize census tracts and then zip codes. The 10 RUCA categories were aggregated into urban (1 to 3) and rural (4 to 10), as recommended by the
WWAMI (Washington, Wyoming, Alaska, Montana, and Idaho) Rural Health Research Center.
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for ongoing screening for cancer survivors. Most BRCA1/2 carriers
$ 35 years old had a bilateral salpingo-oophorectomy, but only one
carrier had a prophylactic mastectomy. Available evidence indicates
that women undergo risk-reducing surgeries over time, well be-
yond the first year.67,68 Thus, longer-term assessments of risk man-
agement behaviors and decision-making factors postcounseling
require further study.
The study’s results have implications for care delivery and
policy. Noninferiority of telephone counseling at 1 year provides
additional evidence that telephone-delivered genetic counseling
and testing could expand access to BRCA1/2 counseling. Telephone
counseling can improve access from geographically remote areas,
ease the travel and care burden for patients traveling to a clinic, and
increase perceived control when patients are given a choice about
their preferred counseling mode. It can also address the limited
genetic counseling work force as the demand for clinical genetic
services increases.20,69 However, it is not clear whether telephone
counseling is noninferior for women who test BRCA1/2 positive,
have variants of uncertain significance, and seek multigene testing.
Furthermore, telephone counseling strategies would have to be
reassessed in the general population in women without a previous
diagnosis of cancer.
National best practice guidelines recommend that trained
cancer genetic professionals provide comprehensive cancer ge-
netics risk assessment to women who meet testing criteria.
However, it is estimated that less than one-third of these women
receive genetic counseling.29,30,66 During our recruitment process,
we observed low rates of prior counseling and testing utilization by
women with a personal history of cancer (30%), providing ad-
ditional evidence for low rates of accessing genetic counseling and
Table 4. Noninferiority of Telephone Counseling to In-Person Counseling on Psychosocial, Quality-of-Life, and Informed Decision–Making Outcomes Per-Protocol
Analysis
Outcome Mean Difference 97.5% CI Noninferiority Margin*
Anxiety 0.08 20.52 to 0.45 5
Cancer-specific distress 0.66 21.75 to 2.28 4
Quality of life: physical health 20.39 21.35 to 1.06 22.5
Quality of life: mental health 0.30 20.83 to 2.26 22.5
Decisional conflict 20.12 23.69 to 2.03 4
Decisional regret 20.31 24.25 to 2.29 5
Perceived personal control 20.01 20.06 to 0.06 20.2
*A noninferiority test tests that the telephone counseling mean is not worse than the in-person counseling mean (as the referencemean) by more than the prespecified
noninferiority margin.
−0.2
5
4
−2.5
−2.5
4
5
Perceived personal control
Decisional regret
Decisional conflict
Quality of life: mental,
change from baseline
Quality of life: physical,
change from baseline
Cancer-related distress,
change from baseline
Anxiety,
change from baseline
−5 −2.5 0 2.5 5
Group difference
(TEL-GC minus IP-GC)
One-Sided 97.5% CI Noninferiority range
Fig 2. Effects and noninferiority ranges 1 year
after the last intervention. GC, genetic coun-
seling; IP, in person; TEL, telephone.
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testing. To our knowledge, our population-based recruitment
approach to deliver remote cancer genetic services is unprec-
edented. It is noteworthy that the Utah Cancer Registry was
able to contact 91.5% of potentially eligible cancer survivors, and
89.8% of eligible survivors who were invited to participate in the
study accepted genetic counseling. Cancer registries have primarily
focused on collecting epidemiologic data. Our study exemplifies
how cancer registries can help implement health promotion in-
terventions with survivors and their at-risk family members.
Furthermore, patient contact through registries may be an effective
public health strategy for expanding access to telephone counseling
at a lower cost than in-person counseling27,28 to large numbers of
people whomay benefit from such services.70-73 Involving patients’
providers, especially in follow-up of test results and recommen-
dations, is likely to maximize program effectiveness.
Recent discussions about population-wide BRCA testing have
been spurred by new findings that it is not uncommon for BRCA1
and BRCA2 mutations to be identified in individuals without
a clear indication for testing. Recent estimates suggest that pop-
ulation screening would identify a mutation in approximately one
in 300 women.74,75 Evidence-based alternative counseling models,
such as telephone counseling, could be implemented as part of
comprehensive precision cancer prevention approaches that in-
volve genetic testing.
Table 5. Breast and Ovarian Cancer Risk Management* by BRCA1/2 Testing Status and Intervention Arm at 1-Year Follow-Up
Cancer Case/Relative Test Status
Screening by Guideline
Recommended Age No. of Participants† Overall In Person Telephone
Previous cancer diagnosis
BRCA1/2 positive (n = 16) (n = 6) (n = 8)
CBE (. 25 years old) 14 11 (78.6%) 6 (100%) 5 (62.5%)
Mammogram (. 25 years old) 14 10 (71.4%) 6 (100%) 4 (50.0%)
Breast MRI (. 25 years old) 14 7 (50.0%) 3 (50.0%) 4 (50.0%)
PM 14 1 (7.1%) 0 (0%) 1 (12.5%)
(n = 7) PO ($ 35 years old) 7 5 (71.4%) 3 of 3 (100%) 2 of 4 (50.0%)
(n = 0) PO (, 35 years old) 0 0 (0%) 0 (0%) 0 (0%)
BRCA1/2 negative‡ (n = 2) (n = 1) (n = 1)
CBE 2 1 (50.0%) 1 (100%) 0 (0%)
Mammogram 2 1 (50.0%) 1 (100%) 0 (0%)
Breast MRI 2 0 (0%) 0 (0%) 0 (0%)
Uninformative§ (n = 191) (n = 82) (n = 74)
CBE 156 132 (84.6%) 70 (85.4%) 62 (83.8%)
Mammogram 156 133 (85.3%) 71 (86.6%) 62 (83.8%)
Breast MRI 156 10 (6.4%) 5 (6.1%) 5 (6.8%)
Nontester (n = 492) (n = 198) (n = 226)
CBE 424 375 (88.4%) 178 (89.9%) 197 (87.2%)
Mammogram 424 377 (88.9%) 177 (89.4%) 200 (88.5%)
Breast MRI 424 15 (3.5%) 4 (2.0%) 11 (4.9%)
Unaffected at-risk relative
BRCA1/2 positive (n = 6) (n = 4) (n = 2)
CBE (. 25 years old) 6 3 (50.0%) 2 (50.0%) 1 (50.0%)
Mammogram (. 25 years old) 6 2 (33.3%) 1 (25.0%) 1 (50.0%)
Breast MRI (. 25 years old) 6 1 (16.7%) 1 (25.0%) 0 (0%)
PM 6 2 (33.3%) 2 (50.0%) 0 (0%)
Chemoprevention 6 0 (0%) 0 (0%) 0 (0%)
(n = 4) PO ($ 35 years old) 3 1 (33.3%) 1 of 3 (33.3%) 0 of 0 (0%)
(n = 3) PO (, 35 years old) 2 0 (0%) 0 of 0 (0%) 0 of 2 (0%)
BRCA1/2 negative (n = 4) (n = 3)
(n = 9) CBE ($ 40 years old) 7 7 (100%) 4 (100%) 3 (100%)
Mammogram ($ 40 years old) 7 7 (100%) 4 (100%) 3 (100%)
(n = 2) (n = 1)
(n = 4) CBE (, 40 years old) 3 2 (66.7%) 2 (100%) 0 (0%)
Mammogram (, 40 years old) 3 1 (33.3%) 1 (50.0%) 0 (0%)
Nontester (n = 2) (n = 1) (n = 1)
CBE (. 25 years old) 2 1 (50.0%) 0 (0%) 1 (100%)
Mammogram (. 25 years old) 2 0 (0%) 0 (0%) 0 (0%)
Breast MRI (. 25 years old) 2 0 (0%) 0 (0%) 0 (0%)
PM 2 0 (0%) 0 (0%) 0 (0%)
Chemoprevention 2 0 (0%) 0 (0%) 0 (0%)
(n = 0) PO ($ 35 years old) 0 0 (0%) 0 of 0 (0%) 0 of 0 (0%)
(n = 2) PO (, 35 years old) 2 0 (0%) 0 of 1 (0%) 0 of 1 (0%)
NOTE. Percent of participants younger than 40 years of age are as follows: cancer case, seven of 701 participants (1%); at-risk relative, 12 of 21 participants (57%).
Abbreviations: CBE, clinical breast examination; MRI, magnetic resonance imaging; PM, prophylactic mastectomy; PO, prophylactic oophorectomy.
*Those included in the analysis reported that at least one breast or ovary was present at baseline; age-eligible women were considered for specific screening and
prophylactic surgery outcomes.
†These numbers include only those who responded to the baseline and the 6- and/or 12-month surveys.
‡Test result negative is defined as a person who tested negative for a known mutation.
§Test result uninformative is defined as no pathogenic mutation identified in the family, and the cause of the cancer risk remains unknown.
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Our study had several limitations. Because our sample was
from a single state, was largely non-Hispanic white, and had
a personal history of cancer, our study may have limited gener-
alizability. Furthermore, our findings may be generalizable only to
settings where patients are counseled by board-certified genetic
counselors because adherence to best practices differs by provider
type.17,76 The small number of women who obtained genetic
testing limits our ability to draw meaningful conclusions about
the noninferiority of telephone counseling for risk management
outcomes. Our sample may not be representative of patients who
are physician- or self-referred for genetic counseling/testing, or
who are referred for urgent testing to help make immediate
treatment decisions. The small number of mutation carriers
limited our ability to draw meaningful conclusions about uptake of
prophylactic surgeries. We did not assess behavioral intent to
undergo surveillance or prophylactic surgery. Finally, our results
may not be generalizable to rapidly evolving multigene panel
testing, which poses challenges for risk communication, especially
given uncertainties about cancer risks and medical management.77
In conclusion, this study provides strong long-term evidence
that telephone counseling for women at risk of HBOC is not
inferior to in-person counseling with regard to fostering informed
decision making, minimizing adverse psychologic and quality-of-
life outcomes, and promoting perceived personal control 1 year
after counseling. Alternative care delivery approaches, such as
telephone communication, can make cancer genetic services more
widely accessible without sacrificing safety.
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Appendix
Table A1. National Comprehensive Cancer Network Risk Management Recommendations41,43
Risk Category Breast and Ovarian Cancer Risk Management
Previous cancer diagnosis*
Test status
BRCA1/2 positive • Follow-up of cancer as recommended by physician
• Annual clinical breast examination starting at 25 years of age
• Annual mammogram starting at 25 years of age
• Annual breast MRI starting at 25 years of age
• Consideration of prophylactic mastectomy
• Recommend prophylactic salpingo-oophorectomy between 35 and 40 years of
age or after childbearing is complete
Negative for familial BRCA1/2 mutation • Follow-up of cancer as recommended by physician
• Annual clinical breast examination
• Annual mammogram
• Imaging with breast MRI may be considered based on personal and family history
Uninformative† or VUS • Follow-up of cancer as recommended by physician
• Annual clinical breast examination
• Annual mammogram
• Imaging with breast MRI may be considered based on personal and family history
No testing done • Follow-up of cancer as recommended by physician
• Annual clinical breast examination
• Annual mammogram
• Imaging with breast MRI may be considered based on personal and family history
Unaffected relative at risk of a familial mutation
Test status
BRCA1/2 positive • Annual clinical breast examination starting at 25 years of age
• Annual mammogram starting at 25 years of age
• Annual breast MRI starting at 25 years of age
• Consideration of prophylactic mastectomy
• Recommend prophylactic salpingo-oophorectomy between 35 and 40 years of
age or after childbearing is complete
• Consider chemoprevention (eg, tamoxifen)‡
BRCA1/2 negative with known familial mutation§ • Clinical breast examination every 3 years until 40 years of age; then annually
• Annual mammogram starting at 40 years of age
No testing done • Annual clinical breast examination starting at 25 years of age
• Annual mammogram starting at 25 years of age
• Annual breast MRI starting at 25 years of age
• Consideration of prophylactic mastectomy
• Consideration of prophylactic salpingo-oophorectomy between 35 and 40 years of
age or after childbearing is complete
• Consider chemoprevention (eg, tamoxifen)‡
Abbreviations: MRI, magnetic resonance imaging; VUS, variant of uncertain significance.
*There are less specific guidelines for patients with cancer. Recommendations depend on the individual’s cancer history and are made in consultation with their
oncologist. For example, patients with cancer may take estrogen inhibitors (ie, tamoxifen) as treatment rather than chemoprevention, as is the case for unaffected
relatives.
†Test result uninformative is defined as no pathogenic mutation identified in the family, and the cause of the cancer risk remains unknown.
‡The survey assessed chemoprevention only in the at-risk family member group because these drugs are often used for treatment in people with a cancer diagnosis.
§For those in this category, it is important to consider cancer history from the other side of the family.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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